Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction
- 1 April 1994
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 73 (11) , 729-736
- https://doi.org/10.1016/0002-9149(94)90872-9
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial.Circulation, 1992
- Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin for Acute Myocardial InfarctionAnnals of Internal Medicine, 1991
- Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study.Circulation, 1991
- Optimizing thrombolytic therapy of acute myocardial infarction.Circulation, 1990
- Optimal utilization of thrombolytic therapy for acute myocardial infarction: Concepts and controversiesJournal of the American College of Cardiology, 1990
- Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1989
- Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trialJournal of the American College of Cardiology, 1988
- Failure of Simple Clinical Measurements to Predict Perfusion Status after Intravenous ThrombolysisAnnals of Internal Medicine, 1988
- Update from the thrombolysis in myocardial infarction trialJournal of the American College of Cardiology, 1987
- Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapyThe American Journal of Cardiology, 1987